Retatrutide

Overview

Retatrutide (development code LY3437943) is a synthetic peptide engineered to activate three separate hormone receptors from a single molecule, rather than the single-receptor approach of earlier metabolic peptides. It belongs to a newer generation of “multi-agonist” incretin-based compounds developed following the success of single- and dual-receptor GLP-1 therapies.

Proposed Mechanism

Activates three metabolic receptors at once — GLP-1, GIP, and glucagon — which together slow gastric emptying, increase satiety signalling, and raise energy expenditure through glucagon receptor activity.

Research Context

Research on retatrutide centers on body weight, body composition (fat mass versus lean mass), and markers of glycaemic control in individuals with obesity or type 2 diabetes. Because it engages three receptor pathways rather than one, a specific research question has been whether the added glucagon-receptor activity meaningfully increases energy expenditure on top of the appetite-suppressing effects shared with GLP-1-only compounds.

Evidence Status — Well-documented

Published phase 2 clinical trial data exists. Longer-term cardiovascular and safety data beyond trial duration is still accumulating.

Public evidence includes published Phase 2 randomized controlled trial data in human subjects, which places it ahead of many research peptides on this list in terms of trial rigor. What remains less established in the public literature is long-duration cardiovascular outcome data and safety data beyond the trial period studied so far — the kind of evidence regulators typically require before a full approval decision.

Research Use Only

This page is a scientific reference summarizing publicly available research literature. It contains no dosing, administration, or protocol guidance, and nothing here constitutes medical advice. BactoCore does not sell this or any peptide referenced in this index — the only product sold directly is bacteriostatic water. See the Safety section for who should not handle research compounds, and the Research Use Disclaimer for full terms.